Linezolid is a synthetic oxazolidinone antibiotic active against a wide range of Gram-positive bacteria, including resistant strains of several species, such as MRSA and penicillin-resistant pneumococci. Linezolid inhibits protein synthesis by binding to domain V of the 23S ribosomal RNA of the 50S subunit of bacterial ribosomes.

Product information

CAS Number: 165800-03-3

Molecular Weight: 337.35

Formula: C16H20FN3O4

Synonym:

Zyvox

Zyvoxid

Zyvoxam

PNU 100766

PNU-100766

PNU100766

U 100766

U-100766

U100766

Chemical Name: N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1, 3-oxazolidin-5-yl]methyl]acetamide

Smiles: CC(=O)NC[C@H]1CN(C2C=CC(=C(F)C=2)N2CCOCC2)C(=O)O1

InChiKey: TYZROVQLWOKYKF-ZDUSSCGKSA-N

InChi: InChI=1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO: 67 mg/mL(198.6 mM).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Linezolid inhibits initiation complex formation with either the 30S or the 70S ribosomal subunits from Escherichia coli. Linezolid inhibits complex formation with Staphylococcus aureus 70S tight-couple ribosomes. Linezolid is a potent inhibitor of cell-free transcription-translation in E. coli, exhibiting 50% inhibitory concentrations (IC50s) of 1.8 mM. Linezolid is an oxazolidinone, a new class of antibacterial agents with enhanced activity against pathogens. Linezolid MICs vary slightly with the test method, laboratory, and significance attributed to thin hazes of bacterial survival, but all workers find that the susceptibility distributions are narrow and unimodal, with MIC values between 0.5 and 4 mg/L for streptococci, enterococci and staphylococci. Linezolid entails mutation of the 23S rRNA that forms the binding site. Linezolid is an oxazolidinone whose mechanism of action involves inhibition of protein synthesis at a very early stage. Linezolid is added to 7H10 agar medium (Difco) supplemented with OADC (oleic acid, albumin, dextrose, and catalase) at 50°C to 56°C by doubling the dilutions to yield a final concentration of 0.125 μg/mL to 4 μg/mL. Linezolid shows excellent in vitro activity against all the strains tested (MICs ≤ 1 μg/ml), including those resistant to SIRE.

References:

1. Noskin GA, et al. Antimicrob Agents Chemother, 1999, 43(8), 2059-2062.
2. Shinabarger DL, et al. Antimicrob Agents Chemother, 1997, 41(10), 2132-2136.
3. Swaney SM, et al. Antimicrob Agents Chemother, 1998, 42(12), 3251-3255.

Products are for research use only. Not for human use.